COLL - Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript
2024-02-22 21:52:10 ET
Collegium Pharmaceutical, Inc. (COLL)
Q4 2023 Earnings Conference Call
February 22, 2024 04:30 pm ET
Company Participants
Christopher James - VP of Investor Relations
Joseph Ciaffoni - President and CEO
Colleen Tupper - EVP and CFO
Scott Dreyer - Chief Commercial Officer
Conference Call Participants
David Amsellem - Piper Sandler
Serge Belanger - Needham & Co.
Leszek Sulewski - Truist Securities
Oren Livnat - H.C. Wainwright
Presentation
Operator
Greetings, and welcome to the Collegium Pharmaceutical Fourth Quarter and Full-Year 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that this conference call is being recorded.
I will now turn the call over to Christopher James, Vice President of Investor Relations at Collegium. Thank you. You may begin.
Christopher James
Welcome to Collegium Pharmaceutical's fourth quarter and full-year 2023 earnings conference call. I'm joined today by Joe Ciaffoni, our Chief Executive Officer; Colleen Tupper, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer.
Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the risk that we may not be able to successfully commercialize our products, that we may incur significant expense and that we may not prevail in current or future litigation pertaining to our business....
Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript